IS Pharma gets exclusive License for Aequasyal

UK based IS Pharma gets exclusive License and Supply rights for Aequasyal oral spray manufactured by

Aequasyal can be used for the lubrication and protection of the oral mucosa in xerostomia in the mouth. Xerostomia is known to be a common symptom in cancer patients.

The spray has the ability to quickly reduce pain and inflammation caused by xerostomia. And therefore, it can be differentiated from other products based on the duration of time over which it works.

Aequasyal is registered as a medical Device across Europe. It is being successfully marketed in France and the US.

IS Pharma has also acquired the option for exclusive rights to Aequasyal in Germany.